Moderna, Inc.

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-16 pm EDT			5-day change	1st Jan Change
125.1 ^USD	+3.01%		+7.81%	+25.83%

Jul. 15	Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing	MT
Jul. 12	China approves CSPC Pharma's RSV vaccine for clinical trials	RE

Moderna snaps up Japan's OriCiro Genomics in mRNA manufacturing push

January 04, 2023 at 07:13 am EST

(Reuters) - Moderna Inc on Wednesday agreed to buy Japan-based OriCiro Genomics for $85 million to boost the U.S. drugmaker's mRNA manufacturing capabilities.

OriCiro's technologies will support Moderna's portfolio of therapeutics and vaccines, the companies said.

(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)

Latest news about Moderna, Inc.

Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing	Jul. 15	MT
China approves CSPC Pharma's RSV vaccine for clinical trials	Jul. 11	RE
Flagship Pioneering Raises $3.6B for 'New Wave' of Health, AI Innovation	Jul. 10	MT
Redburn Raises Moderna's Price Target to $117 From $116	Jul. 10	MT
Bird flu response in Michigan sparks COVID-era worry on farms	Jul. 10	RE
Moderna: partnership for mRNA vaccines in Japan	Jul. 09	CF
Moderna Partners With Mitsubishi Tanabe Pharma to Promote Vaccines in Japan	Jul. 09	MT
Moderna and Mitsubishi Tanabe Pharma Corporation Enter Joint Agreement to Promote Moderna?s Mrna Respiratory Vaccine Portfolio in Japan, Including Covid-19 Vaccines	Jul. 08	CI
HilleVax to discontinue development of norovirus vaccine for infants; shares plummet	Jul. 08	RE
Study finds Pfizer's RSV vaccine not tied to higher risk of pre-term births	Jul. 08	RE
Moderna, Pfizer-BioNTech COVID-19 Vaccine Patent Legal Battle Gets Mixed UK Ruling	Jul. 02	MT
Pfizer-BioNTech, Moderna Set to Appeal Mixed UK Ruling in COVID-19 Vaccine Patent Case	Jul. 02	MT
Moderna: grant for influenza vaccine	Jul. 02	CF
Moderna Receives $176 Million Award to Boost Development of mRNA-Based Pandemic Flu Vaccine	Jul. 02	MT
UK court gives mixed ruling in Pfizer v Moderna COVID vaccine patents case	Jul. 02	RE
Analysis-Scientists wary of bird flu pandemic 'unfolding in slow motion'	Jul. 01	RE
Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell 1000 Value-Defensive Index	Jun. 30	CI
Moderna, Inc.(NasdaqGS:MRNA) dropped from Russell 1000 Defensive Index	Jun. 30	CI
Moderna: positive CHMP opinion on RSV	Jun. 28	CF
Wall Street Set to Open Higher Friday as Key Inflation Data Indicates Cooling Inflation	Jun. 28	MT
Sector Update: Health Care Stocks Higher Pre-Bell Friday	Jun. 28	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Ahead of Key Inflation Report	Jun. 28	MT
Sector Update: Health Care	Jun. 28	MT
Moderna Secures European Medicines Agency's Positive Opinion for mRESVIA	Jun. 28	MT
European Medical Agency's Committee Backs Moderna's RSV Vaccine	Jun. 28	MT

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Sector

Biotechnology & Medical Research

Calendar

2024-08-01 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Moderna's RSV Vaccine Has 'Ample Opportunity' Despite Seasoned Competitors, Oppenheimer Says

June 12, 2024 at 03:38 pm EDT

Moderna, Inc. prepares for the post-Covid era

March 25, 2024 at 10:24 am EDT

Stéphane Bancel, CEO of Moderna: Restoring confidence in the vaccines sector

January 16, 2024 at 03:31 pm EST

More Strategies

Ratings for Moderna, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

125.1 USD

Average target price

145.9 USD

Spread / Average Target

+16.59%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+25.83%	47.96B
LONZA GROUP AG	+45.38%	41.47B
IQVIA HOLDINGS INC.	+0.69%	42.45B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	31.6B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.56B
MEDPACE HOLDINGS, INC.	+49.18%	14.14B
BIO-TECHNE CORPORATION	+3.45%	12.58B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.85%	11.71B

Other Biotechnology & Medical Research

Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Moderna snaps up Japan's OriCiro Genomics in mRNA manufacturing push

Latest news about Moderna, Inc.

Chart Moderna, Inc.

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Moderna, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research